Impact of the Pharmaceutical Care Program for Pharmacological Treatment of Depression in Primary Care on the Compliance to Antidepressants and Patient Wellbeing
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Depression
- Sponsor
- Fundació Sant Joan de Déu
- Enrollment
- 179
- Locations
- 2
- Primary Endpoint
- Adherence to Antidepressant Medication
- Status
- Completed
- Last Updated
- 9 years ago
Overview
Brief Summary
The purpose of this study is to evaluate the impact of pharmaceutical services among patients starting a treatment with antidepressants for a diagnosis of depression. The hypothesis of the study is that pharmacist intervention can improve compliance to antidepressants and patient wellbeing.
Detailed Description
The aim of this study is to evaluate the efficacy of a support program in community pharmacy on the improvement of the compliance to antidepressants and the clinic of typical primary care patients under normal practice circumstances. That implies that the intervention is made by pharmacists without any specific requirement that work in the community pharmacies set up in the area of study and on patients following the usual medical circuit. As well, the cost of the support program is calculated in order to set the effectiveness of the program.
Investigators
Antoni Serrano Blanco
Antoni Serrano Blanco
Fundació Sant Joan de Déu
Eligibility Criteria
Inclusion Criteria
- •Clinical diagnosis for depression from a general practitioner
- •Beginning a pharmacological antidepressant treatment
- •Going to one of the participant community pharmacies
Exclusion Criteria
- •Used antidepressant medication in the past 2 months
- •Had an appointment with an specialist in mental disorders in the past 2 months
- •History of psychotic or bipolar episodes
- •History of drug abuse or dependency
- •Cognitive impairment that not allows assessment
Outcomes
Primary Outcomes
Adherence to Antidepressant Medication
Time Frame: At 3 and 6 months
Adherence to antidepressant medication was measured through Pharmacy records
Secondary Outcomes
- Patient Wellbeing(0, 3 and 6 months)